Compare Chubb Ltd (CB) vs TG Therapeutics Inc (TGTX) Price & Performance

Chubb (CB) trades at $354.74, up 1.99% today, with a bullish technical outlook supported by moving averages and strong fundamental performance. Recent earnings beats, including Q1 2026 EPS of $6.82 versus $6.60 expected, highlight robust profitability with a net income margin of 18.46% and ROE of 16.2%. The company maintains disciplined capital deployment, with a recent $1.02 dividend declared for H1 2026.

The stock offers a compelling value with a P/E of 12.55 and consensus price target of $361.67, though near-term risks include catastrophe losses and softer commercial pricing. Long-term growth is supported by premium expansion and investment income, but investors should monitor underwriting margins and market volatility.

TG Therapeutics (TGTX) trades at $55.01, down 3.69% today, with a bullish technical signal from moving averages and a consensus analyst rating of 'Buy' from 11 of 13 analysts. The company reported strong revenue growth to $616.29 million in 2025 and a net income of $447.18 million, though recent quarterly EPS misses and negative operating cash flow of -$24.77 million highlight volatility. Positive news includes Phase II trials for Briumvi in schizophrenia and Phase I success in myasthenia gravis, driving investor optimism.

Outlook: TGTX offers growth potential through pipeline expansion and robust sales guidance, but faces risks from clinical trial outcomes, cash flow challenges, and high valuation multiples. The stock's 70% year-to-date gain reflects high expectations, requiring careful monitoring of execution against earnings forecasts and regulatory milestones.